Gilead to support generic lenacapavir in low-income nations
Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inCampaigning International News Prevention
Activists demand global access to HIV prevention drug
HIV and sexual health activists protested today at Gilead Sciences' London Office demanding the company…
Posted inNews PrEP Prevention Research
Twice-yearly lenacapavir 89% more effective than Truvada
New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inConferences Healthcare Medicines News PrEP Prevention
Twice-yearly lenacapavir injection sees zero HIV infections in trial
AIDS 2024 Conference Coverage Preliminary findings from the phase III PURPOSE 1 trial revealed that…